Johnson & Johnson may be able to calm investors’ nerves next month when it presents detailed results from the Phase III MARIPOSA study of its bispecific antibody Rybrevant (amivantamab-vmjw) in EGFR-mutated non-small cell lung cancer (NSCLC), now that it has encouraging survival data.
The trial is a major part of the company’s efforts to expand the market for Rybrevant, but although the bispecific antibody succeeded on an interim analysis in April, investors were concerned that the analysis was not enough to stop the trial
On 28 September, J&J’s Janssen Pharmaceutical Companies announced topline results from MARIPOSA, which compares the combination of Rybrevant – a bispecific antibody targeting EGFR and MET – plus the EGFR inhibitor lazertinib against AstraZeneca PLC’s Tagrisso (osimertinib) in patients with locally advanced or metastatic EGFR-mutated NSCLC